nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—EGFR—Docetaxel—skin cancer	0.089	0.13	CbGbCtD
Gefitinib—ORM1—Vismodegib—skin cancer	0.0888	0.13	CbGbCtD
Gefitinib—ORM1—Vemurafenib—skin cancer	0.0702	0.102	CbGbCtD
Gefitinib—ABCG2—Vismodegib—skin cancer	0.0542	0.0791	CbGbCtD
Gefitinib—ABCG2—Vemurafenib—skin cancer	0.0429	0.0625	CbGbCtD
Gefitinib—ALB—Vismodegib—skin cancer	0.0374	0.0545	CbGbCtD
Gefitinib—CYP1A1—Dacarbazine—skin cancer	0.0303	0.0442	CbGbCtD
Gefitinib—ALB—Vemurafenib—skin cancer	0.0295	0.0431	CbGbCtD
Gefitinib—ABCG2—Dactinomycin—skin cancer	0.0285	0.0416	CbGbCtD
Gefitinib—CYP2C19—Vismodegib—skin cancer	0.0242	0.0354	CbGbCtD
Gefitinib—CYP2C9—Vismodegib—skin cancer	0.0201	0.0294	CbGbCtD
Gefitinib—ABCB1—Vismodegib—skin cancer	0.0195	0.0285	CbGbCtD
Gefitinib—ABCG2—Fluorouracil—skin cancer	0.0193	0.0281	CbGbCtD
Gefitinib—CYP3A4—Imiquimod—skin cancer	0.0169	0.0247	CbGbCtD
Gefitinib—CYP3A4—Temozolomide—skin cancer	0.0169	0.0247	CbGbCtD
Gefitinib—ABCG2—Docetaxel—skin cancer	0.0147	0.0215	CbGbCtD
Gefitinib—CYP2D6—Vemurafenib—skin cancer	0.0146	0.0212	CbGbCtD
Gefitinib—ALB—Fluorouracil—skin cancer	0.0133	0.0194	CbGbCtD
Gefitinib—CYP3A4—Vismodegib—skin cancer	0.0117	0.0171	CbGbCtD
Gefitinib—ABCB1—Dactinomycin—skin cancer	0.0103	0.015	CbGbCtD
Gefitinib—CYP3A4—Vemurafenib—skin cancer	0.00926	0.0135	CbGbCtD
Gefitinib—CYP3A5—Docetaxel—skin cancer	0.00815	0.0119	CbGbCtD
Gefitinib—CYP2C9—Fluorouracil—skin cancer	0.00715	0.0104	CbGbCtD
Gefitinib—ABCB1—Docetaxel—skin cancer	0.0053	0.00774	CbGbCtD
Gefitinib—CYP3A4—Docetaxel—skin cancer	0.00318	0.00464	CbGbCtD
Gefitinib—CHEK2—Paclitaxel—Docetaxel—skin cancer	0.00263	1	CbGdCrCtD
Gefitinib—ERBB3—hair follicle—skin cancer	0.00245	0.0381	CbGeAlD
Gefitinib—MKNK2—hair follicle—skin cancer	0.00233	0.0362	CbGeAlD
Gefitinib—IRAK1—hair follicle—skin cancer	0.00233	0.0362	CbGeAlD
Gefitinib—MKNK1—hair follicle—skin cancer	0.0023	0.0357	CbGeAlD
Gefitinib—CSNK1E—nipple—skin cancer	0.00172	0.0267	CbGeAlD
Gefitinib—IRAK4—nipple—skin cancer	0.00169	0.0263	CbGeAlD
Gefitinib—MKNK2—nipple—skin cancer	0.00158	0.0245	CbGeAlD
Gefitinib—MKNK1—nipple—skin cancer	0.00156	0.0242	CbGeAlD
Gefitinib—HIPK4—female reproductive system—skin cancer	0.00154	0.0239	CbGeAlD
Gefitinib—SBK1—head—skin cancer	0.0013	0.0202	CbGeAlD
Gefitinib—EPHA6—female reproductive system—skin cancer	0.00122	0.0189	CbGeAlD
Gefitinib—ERBB3—connective tissue—skin cancer	0.00118	0.0183	CbGeAlD
Gefitinib—MAP2K5—nipple—skin cancer	0.00115	0.0178	CbGeAlD
Gefitinib—MKNK2—connective tissue—skin cancer	0.00112	0.0174	CbGeAlD
Gefitinib—ERBB3—epithelium—skin cancer	0.00112	0.0174	CbGeAlD
Gefitinib—MAP3K19—female reproductive system—skin cancer	0.00111	0.0172	CbGeAlD
Gefitinib—CSNK1E—skin of body—skin cancer	0.0011	0.0171	CbGeAlD
Gefitinib—CYP1A1—skin epidermis—skin cancer	0.00109	0.017	CbGeAlD
Gefitinib—ERBB3—skin of body—skin cancer	0.00106	0.0165	CbGeAlD
Gefitinib—MKNK2—epithelium—skin cancer	0.00106	0.0165	CbGeAlD
Gefitinib—EGFR—mammalian vulva—skin cancer	0.00104	0.0162	CbGeAlD
Gefitinib—EPHA6—head—skin cancer	0.00102	0.0158	CbGeAlD
Gefitinib—CSNK1E—mammalian vulva—skin cancer	0.001	0.0156	CbGeAlD
Gefitinib—IRAK4—mammalian vulva—skin cancer	0.000989	0.0154	CbGeAlD
Gefitinib—MAP3K19—head—skin cancer	0.000924	0.0144	CbGeAlD
Gefitinib—IRAK1—mammalian vulva—skin cancer	0.000922	0.0143	CbGeAlD
Gefitinib—MKNK2—mammalian vulva—skin cancer	0.000922	0.0143	CbGeAlD
Gefitinib—SBK1—lymph node—skin cancer	0.000911	0.0142	CbGeAlD
Gefitinib—MKNK1—mammalian vulva—skin cancer	0.00091	0.0141	CbGeAlD
Gefitinib—IRAK4—lymphoid tissue—skin cancer	0.000878	0.0137	CbGeAlD
Gefitinib—ERBB3—lymphoid tissue—skin cancer	0.000861	0.0134	CbGeAlD
Gefitinib—CSNK1E—female reproductive system—skin cancer	0.00086	0.0134	CbGeAlD
Gefitinib—ERBB3—female reproductive system—skin cancer	0.00083	0.0129	CbGeAlD
Gefitinib—MKNK2—lymphoid tissue—skin cancer	0.000819	0.0127	CbGeAlD
Gefitinib—MKNK1—lymphoid tissue—skin cancer	0.000808	0.0126	CbGeAlD
Gefitinib—CHEK2—lymph node—skin cancer	0.000794	0.0123	CbGeAlD
Gefitinib—MKNK2—female reproductive system—skin cancer	0.000789	0.0123	CbGeAlD
Gefitinib—IRAK1—female reproductive system—skin cancer	0.000789	0.0123	CbGeAlD
Gefitinib—MKNK1—female reproductive system—skin cancer	0.000779	0.0121	CbGeAlD
Gefitinib—STK10—mammalian vulva—skin cancer	0.00075	0.0117	CbGeAlD
Gefitinib—CSNK1E—head—skin cancer	0.000719	0.0112	CbGeAlD
Gefitinib—IRAK4—head—skin cancer	0.000708	0.011	CbGeAlD
Gefitinib—ERBB3—head—skin cancer	0.000694	0.0108	CbGeAlD
Gefitinib—MAP2K5—mammalian vulva—skin cancer	0.000669	0.0104	CbGeAlD
Gefitinib—STK10—lymphoid tissue—skin cancer	0.000666	0.0103	CbGeAlD
Gefitinib—MKNK2—head—skin cancer	0.00066	0.0103	CbGeAlD
Gefitinib—MKNK1—head—skin cancer	0.000651	0.0101	CbGeAlD
Gefitinib—STK10—female reproductive system—skin cancer	0.000642	0.00998	CbGeAlD
Gefitinib—MAP2K5—female reproductive system—skin cancer	0.000573	0.00891	CbGeAlD
Gefitinib—STK10—head—skin cancer	0.000536	0.00834	CbGeAlD
Gefitinib—CYP1A1—nipple—skin cancer	0.000529	0.00823	CbGeAlD
Gefitinib—EGFR—lymph node—skin cancer	0.000523	0.00814	CbGeAlD
Gefitinib—CSNK1E—lymph node—skin cancer	0.000503	0.00782	CbGeAlD
Gefitinib—IRAK4—lymph node—skin cancer	0.000495	0.0077	CbGeAlD
Gefitinib—ERBB3—lymph node—skin cancer	0.000486	0.00755	CbGeAlD
Gefitinib—MAP2K5—head—skin cancer	0.000479	0.00744	CbGeAlD
Gefitinib—ORM1—female reproductive system—skin cancer	0.000465	0.00723	CbGeAlD
Gefitinib—MKNK2—lymph node—skin cancer	0.000462	0.00718	CbGeAlD
Gefitinib—IRAK1—lymph node—skin cancer	0.000462	0.00718	CbGeAlD
Gefitinib—MKNK1—lymph node—skin cancer	0.000456	0.00709	CbGeAlD
Gefitinib—Alopecia—Imiquimod—skin cancer	0.000433	0.00277	CcSEcCtD
Gefitinib—Malnutrition—Imiquimod—skin cancer	0.000426	0.00273	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000423	0.00271	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.000422	0.00271	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.000422	0.00271	CcSEcCtD
Gefitinib—Vomiting—Vismodegib—skin cancer	0.00042	0.00269	CcSEcCtD
Gefitinib—Drug interaction—Docetaxel—skin cancer	0.000419	0.00269	CcSEcCtD
Gefitinib—Rash—Vismodegib—skin cancer	0.000416	0.00267	CcSEcCtD
Gefitinib—Dermatitis—Vismodegib—skin cancer	0.000416	0.00267	CcSEcCtD
Gefitinib—Dermatitis bullous—Fluorouracil—skin cancer	0.000409	0.00262	CcSEcCtD
Gefitinib—Infection—Vemurafenib—skin cancer	0.000405	0.0026	CcSEcCtD
Gefitinib—Nervous system disorder—Vemurafenib—skin cancer	0.0004	0.00256	CcSEcCtD
Gefitinib—Skin disorder—Vemurafenib—skin cancer	0.000396	0.00254	CcSEcCtD
Gefitinib—Respiratory failure—Docetaxel—skin cancer	0.000396	0.00254	CcSEcCtD
Gefitinib—Dehydration—Temozolomide—skin cancer	0.000394	0.00253	CcSEcCtD
Gefitinib—Weight decreased—Bleomycin—skin cancer	0.000393	0.00252	CcSEcCtD
Gefitinib—Nausea—Vismodegib—skin cancer	0.000392	0.00251	CcSEcCtD
Gefitinib—Pneumonia—Bleomycin—skin cancer	0.00039	0.0025	CcSEcCtD
Gefitinib—Angioedema—Imiquimod—skin cancer	0.00039	0.0025	CcSEcCtD
Gefitinib—Dry skin—Temozolomide—skin cancer	0.000389	0.00249	CcSEcCtD
Gefitinib—Hypokalaemia—Temozolomide—skin cancer	0.000386	0.00247	CcSEcCtD
Gefitinib—Malaise—Imiquimod—skin cancer	0.000384	0.00246	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.000382	0.00245	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.000382	0.00245	CcSEcCtD
Gefitinib—Hypotension—Vemurafenib—skin cancer	0.000381	0.00244	CcSEcCtD
Gefitinib—ABCB1—blood vessel—skin cancer	0.00038	0.00591	CbGeAlD
Gefitinib—Stomatitis—Bleomycin—skin cancer	0.000378	0.00242	CcSEcCtD
Gefitinib—STK10—lymph node—skin cancer	0.000376	0.00584	CbGeAlD
Gefitinib—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000374	0.0024	CcSEcCtD
Gefitinib—Cough—Imiquimod—skin cancer	0.000372	0.00238	CcSEcCtD
Gefitinib—Haematuria—Bleomycin—skin cancer	0.000369	0.00237	CcSEcCtD
Gefitinib—Pneumonia—Dactinomycin—skin cancer	0.000364	0.00233	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00036	0.00231	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.000358	0.0023	CcSEcCtD
Gefitinib—Dry skin—Fluorouracil—skin cancer	0.000358	0.0023	CcSEcCtD
Gefitinib—CYP1A1—epithelium—skin cancer	0.000356	0.00554	CbGeAlD
Gefitinib—Dry mouth—Imiquimod—skin cancer	0.000355	0.00228	CcSEcCtD
Gefitinib—Decreased appetite—Vemurafenib—skin cancer	0.000355	0.00227	CcSEcCtD
Gefitinib—Stomatitis—Dactinomycin—skin cancer	0.000352	0.00226	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000352	0.00226	CcSEcCtD
Gefitinib—Fatigue—Vemurafenib—skin cancer	0.000352	0.00225	CcSEcCtD
Gefitinib—Haemoglobin—Bleomycin—skin cancer	0.00035	0.00224	CcSEcCtD
Gefitinib—Constipation—Vemurafenib—skin cancer	0.000349	0.00224	CcSEcCtD
Gefitinib—Haemorrhage—Bleomycin—skin cancer	0.000348	0.00223	CcSEcCtD
Gefitinib—Infection—Imiquimod—skin cancer	0.000346	0.00222	CcSEcCtD
Gefitinib—Shock—Imiquimod—skin cancer	0.000342	0.00219	CcSEcCtD
Gefitinib—Nervous system disorder—Imiquimod—skin cancer	0.000341	0.00219	CcSEcCtD
Gefitinib—CYP1A1—skin of body—skin cancer	0.000339	0.00527	CbGeAlD
Gefitinib—Skin disorder—Imiquimod—skin cancer	0.000338	0.00217	CcSEcCtD
Gefitinib—MAP2K5—lymph node—skin cancer	0.000335	0.00521	CbGeAlD
Gefitinib—Weight decreased—Temozolomide—skin cancer	0.000332	0.00213	CcSEcCtD
Gefitinib—Anorexia—Imiquimod—skin cancer	0.000332	0.00213	CcSEcCtD
Gefitinib—Pneumonia—Temozolomide—skin cancer	0.000329	0.00211	CcSEcCtD
Gefitinib—Infestation NOS—Temozolomide—skin cancer	0.000327	0.0021	CcSEcCtD
Gefitinib—Infestation—Temozolomide—skin cancer	0.000327	0.0021	CcSEcCtD
Gefitinib—Thrombophlebitis—Docetaxel—skin cancer	0.000326	0.00209	CcSEcCtD
Gefitinib—ABCG2—mammalian vulva—skin cancer	0.000326	0.00506	CbGeAlD
Gefitinib—Hepatitis—Dactinomycin—skin cancer	0.000324	0.00208	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000324	0.00208	CcSEcCtD
Gefitinib—Body temperature increased—Vemurafenib—skin cancer	0.000322	0.00207	CcSEcCtD
Gefitinib—Stomatitis—Temozolomide—skin cancer	0.000319	0.00204	CcSEcCtD
Gefitinib—Hepatic failure—Docetaxel—skin cancer	0.000314	0.00201	CcSEcCtD
Gefitinib—Dyspnoea—Imiquimod—skin cancer	0.00031	0.00199	CcSEcCtD
Gefitinib—Hepatobiliary disease—Temozolomide—skin cancer	0.000309	0.00198	CcSEcCtD
Gefitinib—CYP1A1—mammalian vulva—skin cancer	0.000309	0.00481	CbGeAlD
Gefitinib—Alopecia—Bleomycin—skin cancer	0.000307	0.00197	CcSEcCtD
Gefitinib—Erythema multiforme—Dactinomycin—skin cancer	0.000307	0.00197	CcSEcCtD
Gefitinib—Pneumonia—Fluorouracil—skin cancer	0.000303	0.00194	CcSEcCtD
Gefitinib—Decreased appetite—Imiquimod—skin cancer	0.000302	0.00194	CcSEcCtD
Gefitinib—Infestation—Fluorouracil—skin cancer	0.000301	0.00193	CcSEcCtD
Gefitinib—Infestation NOS—Fluorouracil—skin cancer	0.000301	0.00193	CcSEcCtD
Gefitinib—Hypersensitivity—Vemurafenib—skin cancer	0.000301	0.00193	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Imiquimod—skin cancer	0.0003	0.00193	CcSEcCtD
Gefitinib—Fatigue—Imiquimod—skin cancer	0.0003	0.00192	CcSEcCtD
Gefitinib—Atrial fibrillation—Docetaxel—skin cancer	0.000298	0.00191	CcSEcCtD
Gefitinib—Pain—Imiquimod—skin cancer	0.000298	0.00191	CcSEcCtD
Gefitinib—Dermatitis bullous—Docetaxel—skin cancer	0.000295	0.00189	CcSEcCtD
Gefitinib—Haemoglobin—Temozolomide—skin cancer	0.000295	0.00189	CcSEcCtD
Gefitinib—Stomatitis—Fluorouracil—skin cancer	0.000294	0.00188	CcSEcCtD
Gefitinib—Hepatitis—Temozolomide—skin cancer	0.000293	0.00188	CcSEcCtD
Gefitinib—Haemorrhage—Temozolomide—skin cancer	0.000293	0.00188	CcSEcCtD
Gefitinib—Conjunctivitis—Fluorouracil—skin cancer	0.000293	0.00188	CcSEcCtD
Gefitinib—Asthenia—Vemurafenib—skin cancer	0.000293	0.00188	CcSEcCtD
Gefitinib—Urinary tract disorder—Temozolomide—skin cancer	0.00029	0.00186	CcSEcCtD
Gefitinib—Oedema peripheral—Temozolomide—skin cancer	0.000289	0.00185	CcSEcCtD
Gefitinib—Pruritus—Vemurafenib—skin cancer	0.000289	0.00185	CcSEcCtD
Gefitinib—Urethral disorder—Temozolomide—skin cancer	0.000288	0.00184	CcSEcCtD
Gefitinib—Alopecia—Dactinomycin—skin cancer	0.000287	0.00184	CcSEcCtD
Gefitinib—Gastrointestinal pain—Imiquimod—skin cancer	0.000284	0.00182	CcSEcCtD
Gefitinib—Epistaxis—Fluorouracil—skin cancer	0.000284	0.00182	CcSEcCtD
Gefitinib—Anaemia—Bleomycin—skin cancer	0.00028	0.00179	CcSEcCtD
Gefitinib—Diarrhoea—Vemurafenib—skin cancer	0.000279	0.00179	CcSEcCtD
Gefitinib—Erythema multiforme—Temozolomide—skin cancer	0.000277	0.00178	CcSEcCtD
Gefitinib—Urticaria—Imiquimod—skin cancer	0.000276	0.00177	CcSEcCtD
Gefitinib—Abdominal pain—Imiquimod—skin cancer	0.000275	0.00176	CcSEcCtD
Gefitinib—Body temperature increased—Imiquimod—skin cancer	0.000275	0.00176	CcSEcCtD
Gefitinib—Eye disorder—Temozolomide—skin cancer	0.000274	0.00176	CcSEcCtD
Gefitinib—Malaise—Bleomycin—skin cancer	0.000273	0.00175	CcSEcCtD
Gefitinib—Cardiac disorder—Temozolomide—skin cancer	0.000272	0.00175	CcSEcCtD
Gefitinib—ORM1—lymph node—skin cancer	0.000272	0.00423	CbGeAlD
Gefitinib—Haemoglobin—Fluorouracil—skin cancer	0.000272	0.00174	CcSEcCtD
Gefitinib—Haemorrhage—Fluorouracil—skin cancer	0.00027	0.00173	CcSEcCtD
Gefitinib—Angiopathy—Temozolomide—skin cancer	0.000266	0.00171	CcSEcCtD
Gefitinib—CYP1A1—female reproductive system—skin cancer	0.000265	0.00412	CbGeAlD
Gefitinib—Mediastinal disorder—Temozolomide—skin cancer	0.000264	0.0017	CcSEcCtD
Gefitinib—Cough—Bleomycin—skin cancer	0.000264	0.00169	CcSEcCtD
Gefitinib—Dehydration—Docetaxel—skin cancer	0.000262	0.00168	CcSEcCtD
Gefitinib—Anaemia—Dactinomycin—skin cancer	0.000261	0.00167	CcSEcCtD
Gefitinib—Vomiting—Vemurafenib—skin cancer	0.000259	0.00166	CcSEcCtD
Gefitinib—Alopecia—Temozolomide—skin cancer	0.000259	0.00166	CcSEcCtD
Gefitinib—Dry skin—Docetaxel—skin cancer	0.000259	0.00166	CcSEcCtD
Gefitinib—Rash—Vemurafenib—skin cancer	0.000257	0.00165	CcSEcCtD
Gefitinib—Dermatitis—Vemurafenib—skin cancer	0.000257	0.00165	CcSEcCtD
Gefitinib—Hypersensitivity—Imiquimod—skin cancer	0.000256	0.00164	CcSEcCtD
Gefitinib—Malnutrition—Temozolomide—skin cancer	0.000255	0.00164	CcSEcCtD
Gefitinib—CYP2C9—female reproductive system—skin cancer	0.000255	0.00396	CbGeAlD
Gefitinib—Malaise—Dactinomycin—skin cancer	0.000255	0.00163	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000254	0.00163	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000254	0.00163	CcSEcCtD
Gefitinib—Asthenia—Imiquimod—skin cancer	0.00025	0.0016	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000249	0.0016	CcSEcCtD
Gefitinib—Pruritus—Imiquimod—skin cancer	0.000246	0.00158	CcSEcCtD
Gefitinib—Infection—Bleomycin—skin cancer	0.000246	0.00157	CcSEcCtD
Gefitinib—Nausea—Vemurafenib—skin cancer	0.000242	0.00155	CcSEcCtD
Gefitinib—Thrombocytopenia—Bleomycin—skin cancer	0.000242	0.00155	CcSEcCtD
Gefitinib—Arrhythmia—Fluorouracil—skin cancer	0.000242	0.00155	CcSEcCtD
Gefitinib—Alopecia—Fluorouracil—skin cancer	0.000239	0.00153	CcSEcCtD
Gefitinib—ALB—lymph node—skin cancer	0.000239	0.00371	CbGeAlD
Gefitinib—Diarrhoea—Imiquimod—skin cancer	0.000238	0.00153	CcSEcCtD
Gefitinib—Anaemia—Temozolomide—skin cancer	0.000236	0.00151	CcSEcCtD
Gefitinib—Anorexia—Bleomycin—skin cancer	0.000236	0.00151	CcSEcCtD
Gefitinib—Angioedema—Temozolomide—skin cancer	0.000233	0.0015	CcSEcCtD
Gefitinib—Hypotension—Bleomycin—skin cancer	0.000231	0.00148	CcSEcCtD
Gefitinib—Malaise—Temozolomide—skin cancer	0.00023	0.00148	CcSEcCtD
Gefitinib—Infection—Dactinomycin—skin cancer	0.000229	0.00147	CcSEcCtD
Gefitinib—Thrombocytopenia—Dactinomycin—skin cancer	0.000226	0.00145	CcSEcCtD
Gefitinib—Cough—Temozolomide—skin cancer	0.000223	0.00143	CcSEcCtD
Gefitinib—Vomiting—Imiquimod—skin cancer	0.000221	0.00142	CcSEcCtD
Gefitinib—CYP1A1—head—skin cancer	0.000221	0.00344	CbGeAlD
Gefitinib—Weight decreased—Docetaxel—skin cancer	0.000221	0.00141	CcSEcCtD
Gefitinib—Dyspnoea—Bleomycin—skin cancer	0.00022	0.00141	CcSEcCtD
Gefitinib—Anorexia—Dactinomycin—skin cancer	0.00022	0.00141	CcSEcCtD
Gefitinib—Rash—Imiquimod—skin cancer	0.000219	0.00141	CcSEcCtD
Gefitinib—Dermatitis—Imiquimod—skin cancer	0.000219	0.00141	CcSEcCtD
Gefitinib—Pneumonia—Docetaxel—skin cancer	0.000219	0.0014	CcSEcCtD
Gefitinib—Anaemia—Fluorouracil—skin cancer	0.000218	0.00139	CcSEcCtD
Gefitinib—Infestation—Docetaxel—skin cancer	0.000217	0.00139	CcSEcCtD
Gefitinib—Infestation NOS—Docetaxel—skin cancer	0.000217	0.00139	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000216	0.00138	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000216	0.00138	CcSEcCtD
Gefitinib—Decreased appetite—Bleomycin—skin cancer	0.000215	0.00138	CcSEcCtD
Gefitinib—Dry mouth—Temozolomide—skin cancer	0.000213	0.00136	CcSEcCtD
Gefitinib—Stomatitis—Docetaxel—skin cancer	0.000212	0.00136	CcSEcCtD
Gefitinib—Pain—Bleomycin—skin cancer	0.000211	0.00136	CcSEcCtD
Gefitinib—Conjunctivitis—Docetaxel—skin cancer	0.000211	0.00135	CcSEcCtD
Gefitinib—Infection—Temozolomide—skin cancer	0.000207	0.00133	CcSEcCtD
Gefitinib—Nausea—Imiquimod—skin cancer	0.000207	0.00132	CcSEcCtD
Gefitinib—Hepatobiliary disease—Docetaxel—skin cancer	0.000206	0.00132	CcSEcCtD
Gefitinib—Epistaxis—Docetaxel—skin cancer	0.000205	0.00131	CcSEcCtD
Gefitinib—Nervous system disorder—Temozolomide—skin cancer	0.000204	0.00131	CcSEcCtD
Gefitinib—Thrombocytopenia—Temozolomide—skin cancer	0.000204	0.00131	CcSEcCtD
Gefitinib—Skin disorder—Temozolomide—skin cancer	0.000203	0.0013	CcSEcCtD
Gefitinib—Decreased appetite—Dactinomycin—skin cancer	0.0002	0.00128	CcSEcCtD
Gefitinib—Fatigue—Dactinomycin—skin cancer	0.000199	0.00127	CcSEcCtD
Gefitinib—Anorexia—Temozolomide—skin cancer	0.000199	0.00127	CcSEcCtD
Gefitinib—Pain—Dactinomycin—skin cancer	0.000197	0.00126	CcSEcCtD
Gefitinib—Urticaria—Bleomycin—skin cancer	0.000196	0.00126	CcSEcCtD
Gefitinib—Haemoglobin—Docetaxel—skin cancer	0.000196	0.00126	CcSEcCtD
Gefitinib—Body temperature increased—Bleomycin—skin cancer	0.000195	0.00125	CcSEcCtD
Gefitinib—Hepatitis—Docetaxel—skin cancer	0.000195	0.00125	CcSEcCtD
Gefitinib—Haemorrhage—Docetaxel—skin cancer	0.000195	0.00125	CcSEcCtD
Gefitinib—CYP3A4—female reproductive system—skin cancer	0.000194	0.00302	CbGeAlD
Gefitinib—Urinary tract disorder—Docetaxel—skin cancer	0.000193	0.00124	CcSEcCtD
Gefitinib—Oedema peripheral—Docetaxel—skin cancer	0.000192	0.00123	CcSEcCtD
Gefitinib—Urethral disorder—Docetaxel—skin cancer	0.000191	0.00123	CcSEcCtD
Gefitinib—CYP2D6—female reproductive system—skin cancer	0.000191	0.00297	CbGeAlD
Gefitinib—Infection—Fluorouracil—skin cancer	0.000191	0.00122	CcSEcCtD
Gefitinib—Gastrointestinal pain—Dactinomycin—skin cancer	0.000188	0.00121	CcSEcCtD
Gefitinib—Nervous system disorder—Fluorouracil—skin cancer	0.000188	0.00121	CcSEcCtD
Gefitinib—Thrombocytopenia—Fluorouracil—skin cancer	0.000188	0.00121	CcSEcCtD
Gefitinib—Dyspnoea—Temozolomide—skin cancer	0.000186	0.00119	CcSEcCtD
Gefitinib—ABCB1—epithelium—skin cancer	0.000185	0.00288	CbGeAlD
Gefitinib—Erythema multiforme—Docetaxel—skin cancer	0.000185	0.00118	CcSEcCtD
Gefitinib—Anorexia—Fluorouracil—skin cancer	0.000183	0.00117	CcSEcCtD
Gefitinib—Eye disorder—Docetaxel—skin cancer	0.000182	0.00117	CcSEcCtD
Gefitinib—Body temperature increased—Dactinomycin—skin cancer	0.000182	0.00117	CcSEcCtD
Gefitinib—Abdominal pain—Dactinomycin—skin cancer	0.000182	0.00117	CcSEcCtD
Gefitinib—Hypersensitivity—Bleomycin—skin cancer	0.000182	0.00117	CcSEcCtD
Gefitinib—Decreased appetite—Temozolomide—skin cancer	0.000181	0.00116	CcSEcCtD
Gefitinib—Cardiac disorder—Docetaxel—skin cancer	0.000181	0.00116	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Temozolomide—skin cancer	0.00018	0.00115	CcSEcCtD
Gefitinib—Fatigue—Temozolomide—skin cancer	0.00018	0.00115	CcSEcCtD
Gefitinib—Hypotension—Fluorouracil—skin cancer	0.00018	0.00115	CcSEcCtD
Gefitinib—Constipation—Temozolomide—skin cancer	0.000178	0.00114	CcSEcCtD
Gefitinib—Pain—Temozolomide—skin cancer	0.000178	0.00114	CcSEcCtD
Gefitinib—Asthenia—Bleomycin—skin cancer	0.000177	0.00114	CcSEcCtD
Gefitinib—Angiopathy—Docetaxel—skin cancer	0.000177	0.00114	CcSEcCtD
Gefitinib—Mediastinal disorder—Docetaxel—skin cancer	0.000176	0.00113	CcSEcCtD
Gefitinib—Pruritus—Bleomycin—skin cancer	0.000175	0.00112	CcSEcCtD
Gefitinib—Arrhythmia—Docetaxel—skin cancer	0.000174	0.00112	CcSEcCtD
Gefitinib—Alopecia—Docetaxel—skin cancer	0.000172	0.00111	CcSEcCtD
Gefitinib—Dyspnoea—Fluorouracil—skin cancer	0.000171	0.0011	CcSEcCtD
Gefitinib—Gastrointestinal pain—Temozolomide—skin cancer	0.00017	0.00109	CcSEcCtD
Gefitinib—Malnutrition—Docetaxel—skin cancer	0.00017	0.00109	CcSEcCtD
Gefitinib—Hypersensitivity—Dactinomycin—skin cancer	0.00017	0.00109	CcSEcCtD
Gefitinib—Decreased appetite—Fluorouracil—skin cancer	0.000167	0.00107	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000166	0.00106	CcSEcCtD
Gefitinib—Urticaria—Temozolomide—skin cancer	0.000166	0.00106	CcSEcCtD
Gefitinib—Asthenia—Dactinomycin—skin cancer	0.000165	0.00106	CcSEcCtD
Gefitinib—Abdominal pain—Temozolomide—skin cancer	0.000165	0.00106	CcSEcCtD
Gefitinib—Body temperature increased—Temozolomide—skin cancer	0.000165	0.00106	CcSEcCtD
Gefitinib—Pain—Fluorouracil—skin cancer	0.000164	0.00105	CcSEcCtD
Gefitinib—ABCG2—lymph node—skin cancer	0.000163	0.00254	CbGeAlD
Gefitinib—ABCB1—mammalian vulva—skin cancer	0.000161	0.0025	CbGeAlD
Gefitinib—CYP2D6—head—skin cancer	0.00016	0.00248	CbGeAlD
Gefitinib—Diarrhoea—Dactinomycin—skin cancer	0.000158	0.00101	CcSEcCtD
Gefitinib—Vomiting—Bleomycin—skin cancer	0.000157	0.00101	CcSEcCtD
Gefitinib—Anaemia—Docetaxel—skin cancer	0.000157	0.00101	CcSEcCtD
Gefitinib—Rash—Bleomycin—skin cancer	0.000156	0.000999	CcSEcCtD
Gefitinib—Dermatitis—Bleomycin—skin cancer	0.000156	0.000998	CcSEcCtD
Gefitinib—CYP1A1—lymph node—skin cancer	0.000155	0.00241	CbGeAlD
Gefitinib—Hypersensitivity—Temozolomide—skin cancer	0.000154	0.000985	CcSEcCtD
Gefitinib—Urticaria—Fluorouracil—skin cancer	0.000153	0.000978	CcSEcCtD
Gefitinib—Body temperature increased—Fluorouracil—skin cancer	0.000152	0.000974	CcSEcCtD
Gefitinib—Asthenia—Temozolomide—skin cancer	0.00015	0.000959	CcSEcCtD
Gefitinib—Cough—Docetaxel—skin cancer	0.000148	0.00095	CcSEcCtD
Gefitinib—Pruritus—Temozolomide—skin cancer	0.000148	0.000946	CcSEcCtD
Gefitinib—Nausea—Bleomycin—skin cancer	0.000147	0.000941	CcSEcCtD
Gefitinib—Vomiting—Dactinomycin—skin cancer	0.000147	0.00094	CcSEcCtD
Gefitinib—Rash—Dactinomycin—skin cancer	0.000145	0.000932	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000144	0.000921	CcSEcCtD
Gefitinib—Diarrhoea—Temozolomide—skin cancer	0.000143	0.000915	CcSEcCtD
Gefitinib—ABCB1—lymphoid tissue—skin cancer	0.000143	0.00222	CbGeAlD
Gefitinib—Hypersensitivity—Fluorouracil—skin cancer	0.000142	0.000907	CcSEcCtD
Gefitinib—Dry mouth—Docetaxel—skin cancer	0.000141	0.000907	CcSEcCtD
Gefitinib—Infection—Docetaxel—skin cancer	0.000138	0.000883	CcSEcCtD
Gefitinib—ABCB1—female reproductive system—skin cancer	0.000138	0.00214	CbGeAlD
Gefitinib—Nausea—Dactinomycin—skin cancer	0.000137	0.000878	CcSEcCtD
Gefitinib—Shock—Docetaxel—skin cancer	0.000136	0.000875	CcSEcCtD
Gefitinib—Nervous system disorder—Docetaxel—skin cancer	0.000136	0.000872	CcSEcCtD
Gefitinib—Pruritus—Fluorouracil—skin cancer	0.000136	0.000871	CcSEcCtD
Gefitinib—Thrombocytopenia—Docetaxel—skin cancer	0.000136	0.00087	CcSEcCtD
Gefitinib—Skin disorder—Docetaxel—skin cancer	0.000135	0.000863	CcSEcCtD
Gefitinib—Vomiting—Temozolomide—skin cancer	0.000133	0.00085	CcSEcCtD
Gefitinib—Anorexia—Docetaxel—skin cancer	0.000132	0.000847	CcSEcCtD
Gefitinib—Rash—Temozolomide—skin cancer	0.000131	0.000843	CcSEcCtD
Gefitinib—Diarrhoea—Fluorouracil—skin cancer	0.000131	0.000843	CcSEcCtD
Gefitinib—Dermatitis—Temozolomide—skin cancer	0.000131	0.000842	CcSEcCtD
Gefitinib—Hypotension—Docetaxel—skin cancer	0.00013	0.000831	CcSEcCtD
Gefitinib—Nausea—Temozolomide—skin cancer	0.000124	0.000794	CcSEcCtD
Gefitinib—Dyspnoea—Docetaxel—skin cancer	0.000124	0.000792	CcSEcCtD
Gefitinib—Vomiting—Fluorouracil—skin cancer	0.000122	0.000783	CcSEcCtD
Gefitinib—Rash—Fluorouracil—skin cancer	0.000121	0.000777	CcSEcCtD
Gefitinib—Dermatitis—Fluorouracil—skin cancer	0.000121	0.000776	CcSEcCtD
Gefitinib—Decreased appetite—Docetaxel—skin cancer	0.000121	0.000773	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Docetaxel—skin cancer	0.00012	0.000767	CcSEcCtD
Gefitinib—Fatigue—Docetaxel—skin cancer	0.00012	0.000766	CcSEcCtD
Gefitinib—Constipation—Docetaxel—skin cancer	0.000119	0.00076	CcSEcCtD
Gefitinib—Pain—Docetaxel—skin cancer	0.000119	0.00076	CcSEcCtD
Gefitinib—ABCB1—head—skin cancer	0.000115	0.00179	CbGeAlD
Gefitinib—Nausea—Fluorouracil—skin cancer	0.000114	0.000732	CcSEcCtD
Gefitinib—Gastrointestinal pain—Docetaxel—skin cancer	0.000113	0.000727	CcSEcCtD
Gefitinib—Abdominal pain—Docetaxel—skin cancer	0.00011	0.000703	CcSEcCtD
Gefitinib—Body temperature increased—Docetaxel—skin cancer	0.00011	0.000703	CcSEcCtD
Gefitinib—Hypersensitivity—Docetaxel—skin cancer	0.000102	0.000655	CcSEcCtD
Gefitinib—Asthenia—Docetaxel—skin cancer	9.95e-05	0.000638	CcSEcCtD
Gefitinib—Pruritus—Docetaxel—skin cancer	9.81e-05	0.000629	CcSEcCtD
Gefitinib—Diarrhoea—Docetaxel—skin cancer	9.49e-05	0.000608	CcSEcCtD
Gefitinib—Vomiting—Docetaxel—skin cancer	8.82e-05	0.000565	CcSEcCtD
Gefitinib—Rash—Docetaxel—skin cancer	8.74e-05	0.00056	CcSEcCtD
Gefitinib—Dermatitis—Docetaxel—skin cancer	8.73e-05	0.00056	CcSEcCtD
Gefitinib—Nausea—Docetaxel—skin cancer	8.24e-05	0.000528	CcSEcCtD
Gefitinib—ABCB1—lymph node—skin cancer	8.04e-05	0.00125	CbGeAlD
Gefitinib—ERBB3—Signaling by NGF—IL6—skin cancer	2.78e-05	0.000302	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	2.77e-05	0.000302	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	2.77e-05	0.000301	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—KRAS—skin cancer	2.76e-05	0.000301	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—KRAS—skin cancer	2.74e-05	0.000298	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PTGER4—skin cancer	2.73e-05	0.000298	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—KRAS—skin cancer	2.73e-05	0.000297	CbGpPWpGaD
Gefitinib—EGFR—Signaling by SCF-KIT—IL6—skin cancer	2.72e-05	0.000296	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling of activated FGFR—HRAS—skin cancer	2.72e-05	0.000296	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB4—HRAS—skin cancer	2.68e-05	0.000292	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—FOXO4—skin cancer	2.66e-05	0.000289	CbGpPWpGaD
Gefitinib—MKNK1—Disease—PTGS2—skin cancer	2.64e-05	0.000287	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.62e-05	0.000286	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SHH—skin cancer	2.62e-05	0.000285	CbGpPWpGaD
Gefitinib—ERBB3—Disease—ERCC2—skin cancer	2.61e-05	0.000284	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling of activated FGFR—IL6—skin cancer	2.6e-05	0.000284	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—RASA1—skin cancer	2.6e-05	0.000283	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TP53—skin cancer	2.58e-05	0.000281	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—KRAS—skin cancer	2.58e-05	0.000281	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—GLI2—skin cancer	2.57e-05	0.00028	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—CDK4—skin cancer	2.56e-05	0.000279	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB4—IL6—skin cancer	2.56e-05	0.000279	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—FOXO4—skin cancer	2.56e-05	0.000279	CbGpPWpGaD
Gefitinib—EGFR—Downstream signal transduction—HRAS—skin cancer	2.56e-05	0.000279	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PLIN2—skin cancer	2.55e-05	0.000278	CbGpPWpGaD
Gefitinib—EGFR—EGF/EGFR Signaling Pathway—HRAS—skin cancer	2.54e-05	0.000277	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR—HRAS—skin cancer	2.54e-05	0.000277	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—BRAF—skin cancer	2.54e-05	0.000277	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB2—HRAS—skin cancer	2.53e-05	0.000276	CbGpPWpGaD
Gefitinib—EGFR—DAP12 signaling—HRAS—skin cancer	2.52e-05	0.000274	CbGpPWpGaD
Gefitinib—EGFR—Disease—SHH—skin cancer	2.5e-05	0.000272	CbGpPWpGaD
Gefitinib—EGFR—Disease—ENO2—skin cancer	2.5e-05	0.000272	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	2.48e-05	0.00027	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTCH1—skin cancer	2.48e-05	0.00027	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SMO—skin cancer	2.48e-05	0.00027	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	2.47e-05	0.000269	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HRAS—skin cancer	2.46e-05	0.000268	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MC1R—skin cancer	2.46e-05	0.000267	CbGpPWpGaD
Gefitinib—EGFR—Downstream signal transduction—IL6—skin cancer	2.45e-05	0.000267	CbGpPWpGaD
Gefitinib—ERBB3—Disease—TERT—skin cancer	2.44e-05	0.000266	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—KRAS—skin cancer	2.44e-05	0.000266	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR—IL6—skin cancer	2.44e-05	0.000265	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB2—IL6—skin cancer	2.42e-05	0.000264	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—GLI1—skin cancer	2.42e-05	0.000264	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—HRAS—skin cancer	2.42e-05	0.000263	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTGER4—skin cancer	2.41e-05	0.000263	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PLIN2—skin cancer	2.41e-05	0.000263	CbGpPWpGaD
Gefitinib—EGFR—DAP12 signaling—IL6—skin cancer	2.41e-05	0.000263	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	2.39e-05	0.00026	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—TP53—skin cancer	2.38e-05	0.000259	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—HRAS—skin cancer	2.37e-05	0.000258	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	2.37e-05	0.000258	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—HRAS—skin cancer	2.37e-05	0.000258	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL6—skin cancer	2.35e-05	0.000256	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—HRAS—skin cancer	2.35e-05	0.000256	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.33e-05	0.000254	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—HRAS—skin cancer	2.33e-05	0.000254	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—HRAS—skin cancer	2.32e-05	0.000252	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—IL6—skin cancer	2.31e-05	0.000252	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SUFU—skin cancer	2.29e-05	0.00025	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—BRAF—skin cancer	2.29e-05	0.000249	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—IL6—skin cancer	2.29e-05	0.000249	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—IL6—skin cancer	2.27e-05	0.000247	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—IL6—skin cancer	2.27e-05	0.000247	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	2.27e-05	0.000247	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—NRAS—skin cancer	2.26e-05	0.000246	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—IL6—skin cancer	2.25e-05	0.000245	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TERT—skin cancer	2.25e-05	0.000245	CbGpPWpGaD
Gefitinib—EGFR—Focal Adhesion—HRAS—skin cancer	2.24e-05	0.000244	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—IL6—skin cancer	2.23e-05	0.000243	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—IL6—skin cancer	2.22e-05	0.000242	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—NRAS—skin cancer	2.21e-05	0.00024	CbGpPWpGaD
Gefitinib—EGFR—Immune System—FOXO4—skin cancer	2.21e-05	0.00024	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PLIN2—skin cancer	2.2e-05	0.00024	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—HRAS—skin cancer	2.19e-05	0.000239	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—NRAS—skin cancer	2.17e-05	0.000237	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—FOXO4—skin cancer	2.13e-05	0.000232	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	2.1e-05	0.000229	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—HRAS—skin cancer	2.08e-05	0.000226	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CSPG4—skin cancer	2.06e-05	0.000224	CbGpPWpGaD
Gefitinib—MKNK1—Disease—NRAS—skin cancer	2.05e-05	0.000224	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—PTGS2—skin cancer	2.05e-05	0.000223	CbGpPWpGaD
Gefitinib—EGFR—Disease—FOXO4—skin cancer	2.04e-05	0.000222	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.03e-05	0.000221	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	2.01e-05	0.000219	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—NRAS—skin cancer	2e-05	0.000218	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—IL6—skin cancer	1.99e-05	0.000216	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	1.98e-05	0.000215	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PLIN2—skin cancer	1.97e-05	0.000215	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ENO2—skin cancer	1.95e-05	0.000213	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—KRAS—skin cancer	1.95e-05	0.000212	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CSPG4—skin cancer	1.95e-05	0.000212	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.94e-05	0.000212	CbGpPWpGaD
Gefitinib—ERBB3—Disease—BRAF—skin cancer	1.94e-05	0.000211	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PLIN2—skin cancer	1.93e-05	0.00021	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—KRAS—skin cancer	1.9e-05	0.000207	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—NRAS—skin cancer	1.88e-05	0.000205	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—KRAS—skin cancer	1.87e-05	0.000204	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PLIN2—skin cancer	1.82e-05	0.000198	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PLIN2—skin cancer	1.8e-05	0.000196	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—BRAF—skin cancer	1.78e-05	0.000194	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TERT—skin cancer	1.78e-05	0.000193	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CSPG4—skin cancer	1.77e-05	0.000193	CbGpPWpGaD
Gefitinib—MKNK1—Disease—KRAS—skin cancer	1.77e-05	0.000192	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SHH—skin cancer	1.75e-05	0.000191	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RASA1—skin cancer	1.74e-05	0.000189	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—KRAS—skin cancer	1.72e-05	0.000187	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TERT—skin cancer	1.71e-05	0.000186	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTCH1—skin cancer	1.66e-05	0.000181	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SMO—skin cancer	1.66e-05	0.000181	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—HRAS—skin cancer	1.65e-05	0.00018	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—NRAS—skin cancer	1.65e-05	0.00018	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—KRAS—skin cancer	1.62e-05	0.000176	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—HRAS—skin cancer	1.62e-05	0.000176	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTGER4—skin cancer	1.61e-05	0.000176	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—NRAS—skin cancer	1.6e-05	0.000174	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CSPG4—skin cancer	1.59e-05	0.000173	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HRAS—skin cancer	1.59e-05	0.000173	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—IL6—skin cancer	1.58e-05	0.000172	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PTGS2—skin cancer	1.56e-05	0.00017	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CSPG4—skin cancer	1.55e-05	0.000169	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—IL6—skin cancer	1.55e-05	0.000168	CbGpPWpGaD
Gefitinib—MKNK1—Disease—HRAS—skin cancer	1.5e-05	0.000164	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CSPG4—skin cancer	1.46e-05	0.000159	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—HRAS—skin cancer	1.46e-05	0.000159	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CSPG4—skin cancer	1.45e-05	0.000158	CbGpPWpGaD
Gefitinib—EGFR—Disease—ERCC2—skin cancer	1.45e-05	0.000158	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NRAS—skin cancer	1.44e-05	0.000157	CbGpPWpGaD
Gefitinib—MKNK1—Disease—IL6—skin cancer	1.44e-05	0.000157	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FOXO4—skin cancer	1.43e-05	0.000155	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—NRAS—skin cancer	1.43e-05	0.000155	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TERT—skin cancer	1.42e-05	0.000155	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—KRAS—skin cancer	1.42e-05	0.000155	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—BRAF—skin cancer	1.41e-05	0.000153	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ENO2—skin cancer	1.4e-05	0.000152	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—IL6—skin cancer	1.4e-05	0.000152	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HRAS—skin cancer	1.38e-05	0.00015	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—KRAS—skin cancer	1.37e-05	0.00015	CbGpPWpGaD
Gefitinib—EGFR—Disease—TERT—skin cancer	1.36e-05	0.000148	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—BRAF—skin cancer	1.36e-05	0.000148	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.32e-05	0.000144	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ENO2—skin cancer	1.32e-05	0.000144	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—IL6—skin cancer	1.32e-05	0.000144	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—NRAS—skin cancer	1.32e-05	0.000143	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—NRAS—skin cancer	1.26e-05	0.000137	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—KRAS—skin cancer	1.24e-05	0.000135	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—KRAS—skin cancer	1.23e-05	0.000134	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NRAS—skin cancer	1.22e-05	0.000132	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—NRAS—skin cancer	1.21e-05	0.000132	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HRAS—skin cancer	1.21e-05	0.000132	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ENO2—skin cancer	1.21e-05	0.000131	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLIN2—skin cancer	1.19e-05	0.000129	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.18e-05	0.000128	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HRAS—skin cancer	1.17e-05	0.000127	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL6—skin cancer	1.16e-05	0.000126	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ERCC2—skin cancer	1.13e-05	0.000124	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—KRAS—skin cancer	1.13e-05	0.000123	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—BRAF—skin cancer	1.13e-05	0.000123	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NRAS—skin cancer	1.12e-05	0.000122	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—IL6—skin cancer	1.12e-05	0.000122	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—skin cancer	1.1e-05	0.00012	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NRAS—skin cancer	1.1e-05	0.000119	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—KRAS—skin cancer	1.08e-05	0.000118	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ENO2—skin cancer	1.08e-05	0.000118	CbGpPWpGaD
Gefitinib—EGFR—Disease—BRAF—skin cancer	1.08e-05	0.000117	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ENO2—skin cancer	1.06e-05	0.000115	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HRAS—skin cancer	1.05e-05	0.000115	CbGpPWpGaD
Gefitinib—ERBB3—Disease—KRAS—skin cancer	1.05e-05	0.000114	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—HRAS—skin cancer	1.04e-05	0.000114	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KRAS—skin cancer	1.04e-05	0.000113	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.03e-05	0.000113	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL6—skin cancer	1.01e-05	0.00011	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—IL6—skin cancer	9.98e-06	0.000109	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ENO2—skin cancer	9.95e-06	0.000108	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ENO2—skin cancer	9.87e-06	0.000107	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HRAS—skin cancer	9.64e-06	0.000105	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—KRAS—skin cancer	9.62e-06	0.000105	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CSPG4—skin cancer	9.57e-06	0.000104	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TERT—skin cancer	9.53e-06	0.000104	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KRAS—skin cancer	9.44e-06	0.000103	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.43e-06	0.000103	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL6—skin cancer	9.22e-06	0.0001	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HRAS—skin cancer	9.21e-06	0.0001	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—skin cancer	8.9e-06	9.69e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—skin cancer	8.85e-06	9.63e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NRAS—skin cancer	8.84e-06	9.62e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—IL6—skin cancer	8.82e-06	9.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—skin cancer	8.7e-06	9.48e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—skin cancer	8.55e-06	9.31e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NRAS—skin cancer	8.52e-06	9.28e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—IL6—skin cancer	8.52e-06	9.27e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.46e-06	9.22e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—skin cancer	8.18e-06	8.91e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ERCC2—skin cancer	8.13e-06	8.85e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NRAS—skin cancer	8.06e-06	8.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—NRAS—skin cancer	8.03e-06	8.74e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—skin cancer	8.02e-06	8.74e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—skin cancer	7.83e-06	8.52e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.72e-06	8.4e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ERCC2—skin cancer	7.68e-06	8.36e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—skin cancer	7.68e-06	8.36e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KRAS—skin cancer	7.61e-06	8.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—BRAF—skin cancer	7.54e-06	8.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRAS—skin cancer	7.33e-06	7.99e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—skin cancer	7.33e-06	7.98e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRAS—skin cancer	7.09e-06	7.72e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ERCC2—skin cancer	7e-06	7.63e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—skin cancer	6.93e-06	7.55e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—skin cancer	6.91e-06	7.52e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—skin cancer	6.8e-06	7.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRAS—skin cancer	6.77e-06	7.37e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—skin cancer	6.76e-06	7.36e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—skin cancer	6.52e-06	7.1e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO2—skin cancer	6.51e-06	7.09e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—skin cancer	6.46e-06	7.04e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—skin cancer	6.31e-06	6.87e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ERCC2—skin cancer	6.29e-06	6.85e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—skin cancer	6.23e-06	6.79e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—skin cancer	6.19e-06	6.74e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—skin cancer	6.16e-06	6.71e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ERCC2—skin cancer	6.14e-06	6.68e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—skin cancer	6.1e-06	6.65e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—skin cancer	5.96e-06	6.49e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—skin cancer	5.89e-06	6.42e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—skin cancer	5.87e-06	6.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—skin cancer	5.83e-06	6.35e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ERCC2—skin cancer	5.78e-06	6.3e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ERCC2—skin cancer	5.73e-06	6.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—skin cancer	5.62e-06	6.12e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—skin cancer	5.42e-06	5.91e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—skin cancer	5.37e-06	5.84e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—skin cancer	5.19e-06	5.65e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—skin cancer	5.14e-06	5.59e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—skin cancer	4.97e-06	5.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—skin cancer	4.95e-06	5.39e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—skin cancer	4.88e-06	5.31e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRAS—skin cancer	4.74e-06	5.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—skin cancer	4.74e-06	5.16e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—skin cancer	4.61e-06	5.02e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—skin cancer	4.2e-06	4.57e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—skin cancer	4.08e-06	4.44e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ERCC2—skin cancer	3.78e-06	4.12e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—skin cancer	3.77e-06	4.1e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—skin cancer	3.68e-06	4.01e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—skin cancer	3.63e-06	3.95e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—skin cancer	3.47e-06	3.78e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—skin cancer	3.47e-06	3.78e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—skin cancer	3.44e-06	3.74e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—skin cancer	3.32e-06	3.62e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—skin cancer	2.27e-06	2.47e-05	CbGpPWpGaD
